Kerala's Switch to Generic SMA Drug Natsmart Sparks Protests Over 'Clinical Trial' Labels

The generic spinal muscular atrophy (SMA) drug distributed to children in Kerala is a fully approved medication, not an experimental trial, despite "clinical trial" labels that sparked panic among parents this week. The state government replaced Roche's ₹6-lakh-per-bottle Evrysdi with Natco Pharma's ₹15,900 generic equivalent, Natsmart, to sustain its free treatment program.[1][3][4]

Regulatory officials confirmed that the domestic formulation requires no further efficacy studies before being administered to patients. The Central Drugs Standard Control Organisation (CDSCO) stated that the generic version uses the exact same active ingredient and formulation as the patented drug, making additional clinical trials unnecessary.[1][3]

The controversy centers on Kerala's United Against Rare Diseases (KARE) initiative, which provides fully state-funded SMA therapy to children under the age of 12. Kerala is currently the only Indian state to offer the expensive treatment entirely free of charge to eligible pediatric patients.[3][4]

Spinal muscular atrophy is a rare, progressive genetic disorder that causes severe muscle weakness and can be fatal in its most acute forms. The active molecule, risdiplam, does not cure the condition but modifies messenger RNA to help the body produce survival motor neuron protein, slowing the disease's progression.[3][4]

Historically, the financial burden of SMA treatment has placed it far beyond the reach of most Indian families. The original imported medicine, Evrysdi, costs approximately ₹72 lakh annually during the first two years of treatment, and around ₹56 lakh every year thereafter.[3]

To make the KARE program viable, the Kerala government initially negotiated a reduced procurement price of roughly ₹1.5 lakh per bottle with the Swiss pharmaceutical company Roche. Even with this discount, treating the state's registry of over 100 beneficiaries required an annual budget of nearly ₹30 crore.[3][4]

A major shift in rare disease economics occurred in October 2025, when the Delhi High Court declined Roche's plea for an interim injunction against Natco Pharma. This legal decision allowed the Hyderabad-based manufacturer to introduce its generic risdiplam formulation to the Indian market.[3][4]

Following the court ruling, the Kerala government floated a new tender and selected Natco Pharma to supply the state's SMA medication. The generic Natsmart is priced at a maximum retail price of ₹15,900, representing a 97 percent reduction from the original imported drug's commercial cost.[3][4]

The Label Panic

The transition triggered widespread alarm when families at the SAT Hospital in Thiruvananthapuram received medication bottles explicitly stamped with the words "Physician Sample/Clinical Trial Only." Panicked parents immediately raised concerns that their children were being used as human test subjects without informed consent.[1][3]

The labeling issue quickly escalated into a political dispute, with opposition leaders accusing the state health department of violating the Drugs and Cosmetics Act. Critics questioned the safety of the generic alternative and demanded an inquiry into the procurement process that brought the trial-labeled bottles into a public hospital.[1][3]

Parents whose children had shown measurable physical improvement on the original Roche medication expressed deep reluctance to switch treatments. Advocacy groups, including the Cure SMA Foundation of India, petitioned the government for concrete clinical assurances, arguing that affordability should not supersede proven pediatric safety.[2][4]

"We are absolutely not against the use of generic drugs, and we are a group fighting for affordability," said Archana Vashist Panda, co-founder of Cure SMA India. "However, our request is to include safety along with affordability, and we need to know whether the medicine has been adequately evaluated."[4]

Regulatory and Scientific Backing

Health department officials and hospital administrators moved quickly to clarify that the medication was neither experimental nor part of an active clinical trial. SAT Hospital authorities confirmed that the distributed bottles contained the fully authorized generic formulation approved for routine therapeutic use.[1][3]

Natco Pharma explained that the alarming labels were the result of a specific procurement arrangement under its Patient Assistance Programme. The company emerged as the lowest bidder in the state tender and agreed to supply one free bottle for every three purchased by the government.[1][3]

The free units provided under this rate contract were drawn from promotional sample batches, which legally carry the "Physician Sample/Clinical Trial" designation. Natco emphasized that the powder for oral solution inside the bottles was identical to the commercial stock and had met all regulatory requirements.[1][3]

CDSCO officials corroborated the manufacturer's defense, noting that the bulk drug received formal regulatory approval in April 2025. Because Natsmart is an oral solution containing the same concentration of risdiplam as the innovator drug, federal draft guidance explicitly exempts it from requiring in vivo bioequivalence studies.[1][3]

The Economics of Rare Diseases

Public health experts and medical professionals have strongly backed the state's transition to the generic drug, framing it as a necessary step against exorbitant pharmaceutical monopolies. They argue that affordable domestic manufacturing is the only sustainable way to maintain state-funded rare disease programs.[4]

By procuring the generic alternative, the Kerala government effectively reduces its annual expenditure for SMA treatment from nearly ₹30 crore to a fraction of that amount. Natco's negotiated rate brings the effective cost down to approximately ₹8,500 per bottle when factoring in the free assistance units.[1][4]

Medical specialists note that this drastic reduction in procurement costs could allow the state to vastly expand the KARE program's reach. The previous administration had already announced plans to extend free SMA treatment benefits to patients up to 25 years of age, a move that generic pricing makes financially viable.[3][4]

To alleviate parental anxiety, hospital authorities promptly recalled the specific sample-labeled bottles and replaced them with standard government-supplied stock. Health department counselors have also been deployed to explain to families that only the brand name has changed, while the chemical formulation remains identical.[1][3]

Kerala Health Minister K Muraleedharan defended the procurement decision, stating that the expert committee prioritized Indian-made drugs to ensure quality control and cost-effectiveness. The government maintains that it will not revert to the expensive foreign-manufactured medication, though it has promised to address any lingering clinical concerns raised by parents.[3][4]